Jiangsu Hanbon Science & Technology Co., Ltd. Class A
SSSE:68875525.18
CNY
-0.62
(-2.40%)
ISIN
CNE100007085
Return %
Stock
S&P 500
1Y
-26.87
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Da Bing Zhang
- Full Time Employees
- 716
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Huainan China
- IPO Date
- May 16, 2025
- Website
- hanbon.com.cn
- Similar Companies
- Business
- Jiangsu Hanbon Science & Technology Co., Ltd. is a China-based developer and manufacturer of chromatography separation and purification equipment, automated synthesis instruments, consumables, and integrated downstream bioprocessing solutions. The company operates across specialized life science and chemical engineering segments, providing equipment, consumables, and technical engineering services to pharmaceutical, biopharmaceutical, synthetic biology, natural product, and fine chemical enterprises. Its comprehensive product and service portfolio encompasses preparative and industrial-scale liquid chromatography equipment, including high-pressure liquid chromatography systems, low-pressure bio-chromatography systems, dynamic axial compression columns, and automated continuous simulated moving bed chromatography units; supercritical fluid chromatography systems; downstream filtration and fluid handling equipment, including tangential flow filtration systems, ultrafiltration units, and automated in-line buffer preparation and dilution systems; automated synthesis instrumentation, including solid-phase oligonucleotide synthesizers and peptide synthesizers; chromatographic consumables, comprising polymer and silica-based chromatography packing materials, column hardware, and replacement components; and turnkey technical solutions, comprising separation process development, pilot-scale optimization, scale-up validation, and regulatory compliance services for insulin, peptides, oligonucleotides, antibody therapeutics, and vaccines. Founded in October 1998 and headquartered in Huai'an, Jiangsu Province, China, the company distributes its products domestically and internationally across markets in Asia, Europe, and North America, including Germany, the United Kingdom, South Korea, India, and Norway. In recent developments, the company completed its initial public offering on the Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market) under ticker 688755 in May 2025, raising over 500 million RMB to fund the construction of dedicated manufacturing facilities for 1,000 industrial chromatography separation systems and 2,000 laboratory instruments annually, while expanding its specialized chromatography research and development center. The company has also accelerated strategic initiatives to commercialize proprietary high-performance packing media and broaden downstream technology applications in emerging fields such as radiopharmaceuticals and medical aesthetics.